Preventing Illegal Laboratories and Protecting Public Health Act of 2025
- Bill Number
- H.R. 5747
- Origin Chamber
- House
- Congress
- 119th Congress, Session 1
- Policy Area
- Health
- Status
- Introduced
- Latest Action
- 2025-10-14: Referred to the House Committee on Energy and Commerce.
- Last Updated
- 2026-04-13T18:48:15Z
AI-Generated Summary
Purpose of the Legislation
The "Preventing Illegal Laboratories and Protecting Public Health Act of 2025" (H.R. 5747) aims to enhance biosafety and biosecurity in the United States by regulating the distribution of certain dangerous biological agents and improving oversight of high-security laboratories. It seeks to prevent the misuse of these agents in illegal or unsafe settings while ensuring better coordination and evaluation of facilities that handle them.
Key Provisions
Logbook Requirements for Distributors of Highly Pathogenic Agents (Section 2)
- Program Establishment: The Secretary of Health and Human Services (HHS), through the Administration for Strategic Preparedness and Response (ASPR), must implement a program requiring "covered distributors" (entities that sell, lease, loan, or transfer highly pathogenic agents) to maintain electronic logbooks tracking all such transactions.
- List of Agents: HHS must create and annually update a list of "highly pathogenic agents," defined as biological agents in "risk group 3" or higher (based on NIH guidelines, which classify agents by infection risk and need for containment). This excludes agents already regulated under the Federal Select Agent Program (e.g., those posing severe bioterrorism risks).
- The list is developed within 6 months of enactment, with input from agencies like the CDC, NIH, DHS, USDA, Interior, and Defense, and considers biosafety guidelines.
- Logbook Details: For each transaction, distributors must record:
- Agent name.
- Buyer information (name, address, phone, email, business details).
- Intended use and storage location.
- Date, time, and method of transfer.
- Buyer's signature (physical or electronic, compliant with federal e-signature laws).
- A notice warning of criminal penalties for false information (under 18 U.S.C. § 1001, up to 5 years imprisonment and fines).
- Verification Process: Sales cannot occur without buyer ID verification (e.g., government-issued photo ID or acceptable immigration documents) and confirmation that logbook entries match the ID.
- Retention and Disclosure: Records must be kept for at least 3 years (with successors assuming responsibility on ownership changes). Disclosure is limited to HHS, law enforcement, and health officials for compliance, public health, or national security purposes. Logbooks are exempt from Freedom of Information Act (FOIA) requests.
- Penalties: Entering false information in logbooks is treated as a federal crime under existing law.
Evaluation and Oversight of High-Containment Laboratories (Section 3)
- Oversight Entity: The National Security Advisor, consulting HHS, USDA, Defense, Homeland Security, Interior, and the Director of National Intelligence, must designate one federal entity to conduct periodic strategic evaluations of "high-containment laboratories" (those operating at biosafety level 3 or higher, per CDC/NIH guidelines, which require advanced safeguards for handling risky pathogens).
- Evaluation Topics:
- Assess number, location, mission, capacity, physical security, and risks of these labs (including expansion risks).
- Develop national standards for lab design, construction, operation, and maintenance, in consultation with scientists and considering existing regulations.
- Reporting: The designated entity submits reports to the President and Congress with recommendations on oversight gaps and using labs for public health protection.
- Public Health Biosafety and Biosecurity Team: Established within 1 year, this team serves as a single federal contact point for state, local, Tribal, and territorial agencies on lab oversight, public health impacts, and related issues.
- Feasibility Study for Database: The entity must study creating a secure database on high-containment labs, including owner identity, address, licensing status, violations, and other biosafety data. A report on this study goes to Congress.
- Rule of Construction: The act does not override the existing Federal Select Agent Program.
Significant Changes to Existing Law
- Introduces mandatory logbooks for distributors of non-select highly pathogenic agents, filling a gap in tracking for agents not covered by the stricter Select Agent Program (which focuses on bioterrorism threats like anthrax).
- Creates new federal oversight for high-containment labs, including periodic evaluations, standards, and a dedicated team—previously, oversight was fragmented across agencies without a single coordinator or comprehensive database.
- Adds FOIA exemptions and explicit criminal penalties for logbook falsification, strengthening enforcement beyond current biosafety guidelines.
Potential Impacts
- Government Agencies: Increases workload for HHS/ASPR in managing the agent list and program; requires interagency collaboration for evaluations. Other agencies (e.g., CDC, DHS) gain better data access for biosecurity. State/local officials benefit from the new contact team and potential database for coordinated responses.
- Citizens: Enhances public safety by reducing risks of pathogen misuse (e.g., in illegal labs), potentially preventing outbreaks or bioterrorism. However, it may raise privacy concerns for legitimate researchers due to detailed transaction tracking.
- International Relations: No direct impacts mentioned, but stronger U.S. biosecurity measures could indirectly support global health efforts by preventing pathogen spread or proliferation.
Main Stakeholders Affected
- Covered Distributors: Sellers, lessors, or repositories of highly pathogenic agents (e.g., biotech suppliers, biobanks), who must comply with logbooks and verification, facing new administrative burdens.
- Purchasers and Users: Researchers, labs, and institutions buying or transferring agents, required to provide detailed info and ID, which could slow legitimate scientific work.
- High-Containment Laboratories: Facilities at biosafety level 3+ (e.g., university or government labs), subject to evaluations, standards, and potential database inclusion, affecting operations and funding.
- Government Entities: HHS, CDC, NIH, DHS, USDA, and others involved in consultations, reporting, and enforcement; state/local/Tribal health and law enforcement agencies as beneficiaries of shared information.
- Scientific Community: Consulted on standards but potentially impacted by increased regulation on agent access and lab oversight.
Notable Legal, Constitutional, or Political Implications
- Legal: Reinforces criminal liability for false statements (linking to 18 U.S.C. § 1001) and limits data disclosure to protect sensitive info, balancing transparency with security. Complements but does not replace select agent rules, avoiding conflicts.
- Constitutional: May implicate Fourth Amendment privacy rights through transaction tracking and ID requirements, though restrictions on non-security uses mitigate broader surveillance concerns. FOIA exemption (under 5 U.S.C. § 552(b)(3)) aligns with exemptions for national security but could limit public accountability.
- Political: Promotes bipartisan biosecurity (introduced by Reps. Costa and Valadao), emphasizing prevention of illegal labs amid rising concerns over pandemics and bioterrorism. Could influence future funding for lab infrastructure and interagency coordination.
This summary was generated by AI and may contain inaccuracies. Refer to the official source document for the authoritative text.
Sponsor
Cosponsors (6)
Rep. Valadao, David G. [R-CA-22], Rep. Kiley, Kevin [R-CA-3], Rep. Fong, Vince [R-CA-20], Rep. Lee, Susie [D-NV-3], Rep. Titus, Dina [D-NV-1], Rep. Fitzpatrick, Brian K. [R-PA-1]
Recent Actions
- 2025-10-14: Referred to the House Committee on Energy and Commerce.
- 2025-10-14: Introduced in House
- 2025-10-14: Introduced in House
Bill Versions
- Preventing Illegal Laboratories and Protecting Public Health Act of 2025 — issued 2025-10-14 — PDF (14 pages)